Skip to main content
PharmaCielo Ltd. logo

PharmaCielo Ltd. — Investor Relations & Filings

Ticker · PCLO ISIN · CA71716K1012 LEI · 5493002XOFWMT83TYQ57 TSXV Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2026-04-17 AGM Information
Country CA Canada
Listing TSXV PCLO

About PharmaCielo Ltd.

https://www.pharmacielo.com/

PharmaCielo Ltd. is a global supplier specializing in the cultivation, processing, and distribution of medicinal-grade cannabis extracts and dried flower. The company focuses on ethical and sustainable production, aiming to be a leading partner in the global medicinal cannabis market. Utilizing ideal equatorial conditions, PharmaCielo operates large-scale, high-efficiency production facilities, including 12 hectares of open-air greenhouses, enabling four full crops annually for reliable supply. Its product portfolio includes standardized extracts, such as high-purity CBD Isolate, and both psychoactive and non-psychoactive derivatives. Production adheres to pharmaceutical-quality standards, supported by proprietary genetics maintained in a tissue culture lab and advanced processing facilities ensuring consistency and safety.

Recent filings

Filing Released Lang Actions
News release - English.pdf
AGM Information Classification · 100% confidence The document is a Notice of Annual General Meeting (AGM) of shareholders for Tudor Gold Corp. It details the date, location, agenda items including receiving audited financial statements, election of directors, appointment of auditors, and approval of stock option plans. It also provides instructions for voting by proxy and accessing meeting materials electronically. The document does not contain the actual financial statements or detailed reports but rather serves as an announcement and invitation to the AGM. The length is under 5,000 characters and it references where the meeting materials can be accessed, consistent with a notice rather than the full report or presentation. Therefore, the document fits the category of AGM Information (AGM-R).
2026-04-17 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing PharmaCielo's intention to issue common shares as interest payments on secured debentures. It discusses the terms of the share issuance, regulatory approvals required, and forward-looking statements. There are no financial statements, detailed financial performance data, or comprehensive report content. The document is focused on a financing activity related to capital structure changes (issuing shares to satisfy interest payments). It is not an annual or interim report, audit report, or earnings release. The content fits the definition of a Capital/Financing Update (CAP) as it provides an update on the company's financing activities and capital structure changes.
2026-04-17 English
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Capital/Financing Update Classification · 95% confidence The document is a Form 13-502F1, which is a regulatory filing required by the Ontario Securities Commission (OSC) for reporting issuers to calculate and pay their annual participation fees. It is not an annual report, financial statement, or earnings release, but rather a specific administrative regulatory form. As it does not fit into the specific categories like 10-K, IR, or ER, it falls under the 'Regulatory Filings' (RNS) category as the designated fallback.
2026-02-04 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Capital/Financing Update Classification · 95% confidence The document is a 'Form 13-501F1', which is a regulatory filing used by reporting issuers in Alberta, Canada, to calculate and report their participation fees based on market capitalization. It is a standard regulatory compliance document submitted to a securities commission. Since it does not fit into specific categories like earnings releases, annual reports, or proxy statements, it falls under the 'Regulatory Filings' (RNS) category.
2026-02-04 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 95% confidence The document is a Form 13-502F1, which is a regulatory filing required by the Ontario Securities Commission (OSC) for reporting issuers to calculate and pay their annual participation fees. It contains financial data related to market capitalization and fee calculations but does not constitute an annual report, earnings release, or other standard financial reporting document. As it is a specific regulatory form for fee assessment that does not fit into the other defined categories, it is classified as a Regulatory Filing (RNS).
2026-01-29 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive set of 'Condensed Interim Consolidated Financial Statements' for PharmaCielo Ltd. for the three and six months ended September 30, 2025. It includes detailed financial tables (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Shareholders' Deficit, and Statement of Cash Flows) along with extensive explanatory notes. It is not an announcement or a summary, but the full interim financial report itself, fitting the definition of an Interim/Quarterly Report (IR). H1 2025
2025-12-06 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.